# Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib

> **NCT03094052** · PHASE2 · COMPLETED · sponsor: **University of California, San Francisco** · enrollment: 11 (actual)

## Conditions studied

- HER2-positive Breast Cancer
- Breast Adenocarcinoma
- Stage II Breast Cancer AJCC v6 and v7
- Stage IIA Breast Cancer AJCC v6 and v7
- Stage IIB Breast Cancer AJCC v6 and v7
- Stage III Breast Cancer AJCC v7
- Stage IIIA Breast Cancer AJCC v7
- Stage IIIB Breast Cancer AJCC v7
- Stage IIIC Breast Cancer AJCC v7

## Interventions

- **DRUG:** Neratinib
- **BIOLOGICAL:** Trastuzumab
- **DRUG:** Loperamide
- **DRUG:** Crofelemer
- **DRUG:** Diphenoxylate/Atropine

## Key facts

- **NCT ID:** NCT03094052
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-09
- **Primary completion:** 2022-10-31
- **Final completion:** 2022-10-31
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2025-06-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03094052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03094052, "Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT03094052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*